ClinicaliQ Trial Snapshot
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) — Active Not Recruiting • Phase II • NCT04663308.
- Volixibat tested for reducing itching in patients with PSC and potentially slowing disease progression.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC. Conditions: Primary Sclerosing Cholangitis Interventions: Volixibat, Placebo Lead Sponsor: Mirum Pharmaceuticals, Inc. Planned Enrollment: 182 participants